6/26/2025

Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third-quarter 2025 dividend of $0.43 per share. Alongside these developments, the company reported various clinical trial updates and strategic agreements. Over the last month, Pfizer's share price rose by 4%, slightly outperforming the broader market's 1.7% increase in the past week. These advances, along with sustained dividend distribution, likely reinforced investor...

Source: Yahoo

6/26/2025

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Source: Yahoo

6/26/2025

NEW YORK, June 26, 2025--ADVANCE, the flagship event from Smartly, the leading AI-powered advertising technology platform, returns to New York City on September 17.

Source: Yahoo

6/26/2025

The London Biotechnology Show 2025, held from 18 to 19 June, encompassed a range of sessions on automation, regulation, and innovation, amongst others.

Source: Yahoo

6/26/2025

NEW YORK, June 26, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous HYMPAVZI in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatm

Source: Yahoo

6/26/2025

Pfizer reported positive results on Thursday from a Phase 3 study of Hympavzi, its experimental treatment for hemophilia A or B with inhibitors.The US pharmaceutical company said the trial met its...

Source: Finnhub

6/26/2025

Pfizer Inc. announced positive topline results from the Phase 3 BASIS study evaluating HYMPAVZI?? for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary...

Source: Finnhub

6/26/2025

By Colin Kellaher Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments...

Source: Finnhub

6/26/2025

Pfizer's hemophilia therapy,Hympavzi, met the main goal of a late-stage study in patientswith certain types of antibodies, the U.S. drugmaker said onThursday. The data comes months...

Source: Finnhub

6/26/2025

Pfizer said on Thursday itshemophilia therapy, Hympavzi, met the main goal of a late-stagestudy in patients with certain types of antibodies. The data comes months after Pfizer said it...

Source: Finnhub

6/25/2025

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Source: SeekingAlpha

6/25/2025

NEW YORK, June 25, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by Pfizer.

Source: Yahoo

6/25/2025

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.

Source: SeekingAlpha

6/25/2025

Discover the best large-cap stocks for value and dividend safety using YCharts' Value Score and Ben Graham Formula. Click for my exclusive income stock picks.

Source: SeekingAlpha

6/25/2025

BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

Source: Yahoo

6/25/2025

NEW YORK, June 25, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2025 Performance Report, to be issued that morning.

Source: Yahoo

6/25/2025

Former Pfizer Chief Scientific Officer brings decades of drug development and strategic leadership experience to Arbor’s BoardCAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dr. Dolsten most recently served as Chief Scientific Officer and President of Worldwide Research, Development, and

Source: Yahoo

6/25/2025

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Source: Yahoo

6/25/2025

Source: SeekingAlpha

6/25/2025

Explore May 2025 market volatility, U.S.-China trade talks, and record dividend income growth.

Source: SeekingAlpha